Enlivex Therapeutics Ltd (ENLV)

Jan 10, 2025, 9:00 AM EST - 7 days ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Dec 11, 2024, 8:30 AM EST - 5 weeks ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 6 weeks ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nov 26, 2024, 10:15 AM EST - 7 weeks ago

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Nov 14, 2024, 8:00 AM EST - 2 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Oct 30, 2024, 8:00 AM EDT - 2 months ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Sep 24, 2024, 8:30 AM EDT - 4 months ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Aug 30, 2024, 9:00 AM EDT - 5 months ago

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GP

Jul 19, 2024, 9:00 AM EDT - 6 months ago

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 17, 2024, 8:00 AM EDT - 7 months ago

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

May 29, 2024, 4:15 PM EDT - 8 months ago

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

May 28, 2024, 8:12 AM EDT - 8 months ago

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Apr 16, 2024, 7:50 AM EDT - 9 months ago

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Apr 11, 2024, 2:58 PM EDT - 10 months ago

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Apr 11, 2024, 8:05 AM EDT - 10 months ago

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Mar 22, 2024, 10:50 AM EDT - 10 months ago

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

UMAC

Feb 26, 2024, 8:30 AM EST - 11 months ago

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Feb 21, 2024, 8:30 AM EST - 11 months ago

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Jan 17, 2024, 8:00 AM EST - 1 year ago

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Dec 20, 2023, 8:00 AM EST - 1 year ago

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Jul 31, 2023, 8:00 AM EDT - 1 year ago

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Jun 6, 2023, 8:00 AM EDT - 1 year ago

Enlivex to Present at the 2023 Jefferies Healthcare Conference

May 31, 2023, 8:04 AM EDT - 1 year ago

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

May 8, 2023, 8:00 AM EDT - 1 year ago

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

Apr 19, 2023, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Apr 17, 2023, 8:00 AM EDT - 1 year ago

Enlivex Appoints Andrew Singer to its Board of Directors

Apr 14, 2023, 9:40 AM EDT - 1 year ago

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Apr 12, 2023, 10:45 AM EDT - 1 year ago

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

Apr 4, 2023, 8:00 AM EDT - 1 year ago

Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

Apr 3, 2023, 8:00 AM EDT - 1 year ago

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

Mar 20, 2023, 8:00 AM EDT - 1 year ago

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

Feb 15, 2023, 8:00 AM EST - 2 years ago

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Jan 25, 2023, 8:37 AM EST - 2 years ago

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Dec 5, 2022, 8:00 AM EST - 2 years ago

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

Nov 15, 2022, 8:00 AM EST - 2 years ago

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Oct 3, 2022, 8:13 AM EDT - 2 years ago

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

Sep 30, 2022, 2:08 AM EDT - 2 years ago

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Sep 13, 2022, 8:00 AM EDT - 2 years ago

Enlivex to Present at Upcoming Investor and Media Conferences

Sep 12, 2022, 8:00 AM EDT - 2 years ago

Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Aug 29, 2022, 8:00 AM EDT - 2 years ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells

Aug 24, 2022, 8:00 AM EDT - 2 years ago

Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Aug 22, 2022, 8:00 AM EDT - 2 years ago

Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update

Aug 17, 2022, 8:00 AM EDT - 2 years ago

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Aug 3, 2022, 8:15 AM EDT - 2 years ago

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™

Jul 6, 2022, 8:37 AM EDT - 2 years ago

Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Jun 7, 2022, 8:00 AM EDT - 2 years ago

Enlivex to Present at the 2022 Jefferies Healthcare Conference

May 10, 2022, 8:00 AM EDT - 2 years ago

Enlivex Announces Upcoming May Conference Presentations

May 9, 2022, 9:05 AM EDT - 2 years ago

Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

May 5, 2022, 8:37 AM EDT - 2 years ago

Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra

Apr 29, 2022, 8:41 AM EDT - 2 years ago

Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates